雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Radiotherapy for unresectable stage Ⅲ non-small cell lung cancer Noriko Kishi 1 1Department of Radiation Oncology Kyoto University Hospital Keyword: 非小細胞肺癌 , 切除不能 , 化学放射線療法 pp.73-77
Published Date 2026/1/10
DOI https://doi.org/10.18888/rp.0000003041
  • Abstract
  • Look Inside
  • Reference

The PACIFIC trial showed that consolidation durvalumab after concurrent chemoradiotherapy prolongs overall survival in unresectable stage Ⅲ non-small cell lung cancer(NSCLC), changing clinical practice. The LAURA trial found that in unresectable stage Ⅲ EGFR-mutant NSCLC, osimertinib improved progression-free survival, indicating that molecularly targeted strategies in stage Ⅳ NSCLC are now being introduced in stage Ⅲ NSCLC as well. Reducing toxicity after chemoradiotherapy has become increasingly critical:pulmonary toxicity was the most important adverse event and the main reason patients cannot proceed to consolidation therapy. Recently, concerns about cardiotoxicity has also increased. These consolidations have driven wider adoption of IMRT to decrease toxicities. With advances such as machine learning-assisted treatment planning, adaptive radiotherapy, and high-precision particle therapy, further improvement in loco-regional control and safety are expected.


Copyright © 2026, KANEHARA SHUPPAN Co.LTD. All rights reserved.

基本情報

電子版ISSN 印刷版ISSN 0009-9252 金原出版

関連文献

もっと見る

文献を共有